An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup
Abstract Ethosuximide, the first‐line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an inn...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
格式: | 圖書 |
出版: |
Wiley,
2023-02-01T00:00:00Z.
|
主題: | |
在線閱讀: | Connect to this object online. |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
索引號: |
A1234.567 |
---|---|
復印件 1 | 可用 |